Katja Weisel, MD, of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the role of measurable residual disease (MRD) in the treatment of myeloma and its importance for patients. Dr Weisel also explains that MRD assessment results should be considered with caution as this is not the only measurement and is not definitive of complete remission or relapse. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.